Skip to main content
Clinical Trials/NCT04106596
NCT04106596
Unknown
N/A

Immunogenetic Characteristics in Autoimmune Encephalitis and Related Disorders: HLA Analysis

Hospices Civils de Lyon1 site in 1 country160 target enrollmentOctober 1, 2019

Overview

Phase
N/A
Intervention
Not specified
Conditions
Autoimmune Encephalitis
Sponsor
Hospices Civils de Lyon
Enrollment
160
Locations
1
Primary Endpoint
HLA in autoimmune encephalitis and related disorders
Last Updated
6 years ago

Overview

Brief Summary

Autoimmune encephalitis (AE) are characterized by subacute onset of memory deficits, altered mental status or psychiatric symptoms, frequently associated with seizures, inflammatory cerebrospinal fluid and in cases with prominent limbic involvement, typical magnetic resonance imaging. Several autoantibodies (Ab) may be detected in AE, although its detection is not mandatory to establish a diagnosis. These Ab mainly recognize different synaptic and cell-surface proteins in the central nervous system, and are thought to be pathogenic as they alter the normal location or function of its antigens.

The primary trigger of the immune response is unknown for most of AE. In addition to acquired susceptibility, genetic predisposition may also be important in the pathogenesis of AE. Human leukocyte antigen (HLA) is the genetic factor most frequently associated with autoimmune diseases, due to its genetic complexity and key role in the adaptive immune response. The aim of the study is to describe HLA profile in three groups of autoimmune encephalitis and related disorders: anti-LGI1, anti-CASPR2 and anti-GAD neurological diseases.

Registry
clinicaltrials.gov
Start Date
October 1, 2019
End Date
October 1, 2020
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Presence of anti-LGI1, anti-CASPR2 or anti-GAD antibodies in serum or cerebrospinal fluid;
  • Clinical picture compatible with the detected antibody (limbic encephalitis in anti-LGI1; limbic encephalitis, neuromyotonia or Morvan's syndrome in anti-CASPR2; limbic encephalitis, cerebellar ataxia or stiff-person syndrome in anti-GAD

Exclusion Criteria

  • Absence of complete clinicobiological data.

Outcomes

Primary Outcomes

HLA in autoimmune encephalitis and related disorders

Time Frame: 12 Months

Description of HLA alleles and haplotypes carrier frequencies in autoimmune encephalitis and related disorders

Clinical relevance of HLA in autoimmune encephalitis and related disorders

Time Frame: 12 Months

Description of clinical differences among patients regarding their HLA status

Study Sites (1)

Loading locations...

Similar Trials